1:00 – 1:05 p.m.
WELCOME
John Greenland, MD PhD, UCSF, San Francisco, CA, USA
1:05 – 1:45 p.m.
SESSION 1 - TRANSPLANTATION TOOLS OF THE TRADE
Chair: John Greenland, MD, PhD, University of California San Francisco, San Francisco, CA, USA
1:05 p.m. – Clinical Transplant Medicine: More than Just a Band Aid… (15 minutes)
Ciara Shaver, MD PhD, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Teaching/Discussion Points
- Clinical overview for the basic scientists covering the life of the allograft from donor to patient.
- Clinical presentation of ischemia-reperfusion injury, acute cellular rejection, antibody-mediated rejection, chronic rejection; Compare and contrast heart and lung-specific concepts.
1:20 p.m. – Design and Analysis of Cohorts for Translational Research: Full House (15 minutes)
Edward Cantu III, MD MSCE, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Teaching/Discussion Points
- Describe approaches to designing cohorts for translational studies in thoracic transplantation
- What controls should be considered
- Sources of bias
- Statistical Power
- Survival Analysis (censoring and competing risks)
- Focus on the use of these tools for the study of antibody-mediated rejection
1:35 p.m. – OMICS: Ralph Breaks the Internet (15 minutes)
Edward Cantu III, MD MSCE, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Teaching/Discussion Points
- Genomics, Transcriptomics, Proteomics, Metabolomics
- Considerations for Big Data analysis
- Focus on the use of these tools for the study of ischemia-reperfusion injury
1:50 p.m. – Q&A with Speakers (10 minutes)
2:00 – 3:00 p.m.
SESSION 2 – INFECTION AND IMMUNITY IN THORACIC TRANSPLANTATION
Chair: Esme Dijke, PhD, University of Alberta, Edmonton, Alberta, Canada
2:00 p.m. – They Came from the Swamp: Microbiome (15 minutes)
Tereza Martinu, MD MHS, University of Toronto, Toronto, Ontario, Canada
Teaching/Discussion Points
- Gut and lung microbiome
- Effects of microbiota on immune responses
- Role of microbiome in transplantation
- Microbiome-derived metabolite effects on the immune system.
2:15 p.m. – Streetlight Effect: How to Monitor Post-Transplant Immune Responses (15 minutes)
John Greenland, MD PhD, UCSF, San Francisco, CA, USA
Teaching/Discussion Points
- Strategies to assess immunosuppression level and infection vs. rejection risk
- Elispots (CMV, EBV, TB, allo-reactive etc.)
- Immunoknow; Cell-free DNA
- Microvesicles/cross-dressing
- BAL immunophenotyping/cytokines.
2:30 p.m. – Scylla and Charybdis: How Infections Potentiate Rejection (15 minutes)
Andrew Gelman, PhD, Washington University, St. Louis, MO, USA
Teaching/Discussion Points
- Bacterial activation of pathogen-specific responses (PAMPs, DAMPs)
- Specific case of pseudomonas
- Viral effects on antigen presentation and interferon-dependent immunity
- Heterotopic immune responses.
2:45 p.m. – Q&A with Panel (15 minutes)
3:00 – 3:05 p.m.
BREAK
3:05 – 4:20 p.m.
SESSION 3 – THERAPEUTICS IN THORACIC TRANSPLANTATION
Chair: Tereza Martinu, MD MHS, University of Toronto, Toronto, Ontario, Canada
3:05 p.m. – Mechanisms of Immunosuppression: The Empire Strikes Back (15 minutes)
Eric Epailly, MD, Centre Hospitalier de l’Université de Strasbourg, Strasbourg, France
Teaching/Discussion Points
- Molecular pathways and specific cell types targeted by current immunosuppressants
- How these mechanisms play into the effects of immunosuppression
3:20 p.m. – Novel Agents in the Pipeline: A New Hope (15 minutes)
Glen Westall, MD PhD, Alfred Hospital, Melbourne, Australia
Teaching/Discussion Points
- New agents being developed for immunosuppression or immunomodulation and their mechanisms of action
3:35 p.m. – Infinity Wars: Will Tolerance Prevail? (15 minutes)
Joren Madsen, MD Dphil, Massachusetts General Hospital, Boston, MA, USA
Teaching/Discussion Points
- Operational definitions of tolerance
- Types of regulatory cells
- Current strategies to achieving tolerance in pre-clinical and clinical thoracic transplantation
3:50 p.m. – Cell Therapy in Transplantation: The Force Awakens (15 Minutes)
Daniel Chambers, MD,The Prince Charles Hospital, Brisbane, Australia
Teaching/Discussion Points
- Current state on cell therapy in transplantation
- Different types of cell therapy; Future directions
- Can cell therapy make use of ex-vivo organ perfusion?
4:05 p.m. – Q&A with Panel (15 minutes)
4:20 p.m.
SUMMARY / EVALUATION
John Greenland, MD PhD, UCSF, San Francisco, CA, USA